Results 191 to 200 of about 108,172,160 (276)

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Journal of Internal Medicine, Volume 300, Issue 5, Page 590-609, November 2026.
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund, Johanna Melin, Anju E. Joham, Terhi T. Piltonen, D. Aled Rees, Helena J. Teede   +5 more
wiley   +1 more source

Plasma Plasminogen Activator Inhibitor-1 as a Biomarker for Disease Activity and Pharmaco-Response Prediction in Pediatric Epilepsy: A Prospective Cohort Study. [PDF]

Neuropsychiatr Dis Treat
Xiao X, Shi XY, Feng J, Zhou XY, Wang ML, Zhang BB, Xu C, Tang JH.   +7 more
europepmc   +1 more source

From Dysbiosis to Disease: How Vaginal Microbiota Shape Group B Streptococcus Pathogenesis

ChemBioChem, Volume 27, Issue 20, 28 October 2026.
Lactobacillus crispatus plays a critical role in the vaginal microbiome. Limiting glucose shifts metabolism toward HMO consumption and amino acid metabolism. These actions enable alkali production and competition. Homeostasis, characterized by dense Lactobacilli colonization and suppression of pathogens, provides resistance to dysbiosis.
Julie A. Talbert, Steven D. Townsend
wiley   +1 more source

Plasminogen Activator Inhibitor-1 in Skin Malignancies: Therapeutic Implications of Its Inhibition. [PDF]

Biomolecules
Fujimura T, Muto Y, Asano Y.
europepmc   +1 more source

Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections

Chemistry – A European Journal, Volume 32, Issue 39, 22 October 2026.
Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley   +1 more source

Plasminogen activator Inhibitor-1 in systemic sclerosis: A nexus of fibrosis, vasculopathy, and senescence. [PDF]

Biomed J
Takahashi T, Takahashi T, Asano Y.
europepmc   +1 more source

4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status. [PDF]

Thromb J
Zhang X, Guo X.
europepmc   +1 more source

Roles of plasminogen activator inhibitor-1 in aging-related muscle and bone loss in mice. [PDF]

Aging (Albany NY)
Ohira T, Kawao N, Mizukami Y, Okada K, Nishikawa A, Yamao H, Yamada A, Kaji H.   +7 more
europepmc   +1 more source

Acute portal vein thrombosis in an elderly man with homozygous mutations of plasminogen activator inhibitor-1 and methylenetetrahydrofolate reductase genes. [PDF]

Arch Med Sci
Chen J, Zhao H, Yang S, Lu H, Qi X.
europepmc   +1 more source

Myocardial Infarction in a Patient With Homozygous Plasminogen Activator Inhibitor-1 (PAI-1) 4G/4G Mutation: A Case Report. [PDF]

Cureus
Manasrah A, Khan F, Yarkoni A, Kashou H, Rehman A.   +4 more
europepmc   +1 more source